BRAF突变及功能分类对晚期NSCLC临床结局无负面影响并与免疫治疗敏感性相关
该研究纳入2009至2019年德国两个肺癌中心精准肿瘤项目中72例晚期或复发NSCLC患者,进行BRAF突变亚型分析。结果显示BRAF突变型NSCLC总生存劣于野生型(HR 1.38,p=0.048),但生存结局不受BRAF突变功能分类影响;BRAF突变型NSCLC对免疫检查点抑制剂表现出较高敏感性。
要点
- BRAF突变型NSCLC总生存劣于野生型(HR 1.38,p=0.048)。
- BRAF突变功能分类不影响生存结局。
- BRAF突变型NSCLC对免疫检查点抑制剂敏感性较高。
核心结论
- BRAF突变型NSCLC预后较差,但该预后不受BRAF突变功能分类决定。
- 与其他可靶向驱动突变NSCLC不同,BRAF突变型NSCLC对免疫检查点抑制剂表现出高敏感性。
研究设计与样本
- 研究纳入2009至2019年德国两个大型肺癌中心精准肿瘤项目中连续入组的转移性或复发性NSCLC患者,共72例。
- 研究对BRAF突变进行功能分类亚型分析,并评估BRAF V600E靶向治疗的特定影响。
主要发现
- 72例患者中,p.V600E突变31例(43%),功能II/III类BRAF突变亚型41例(57%),涵盖18种不同亚型。
- 功能相关共突变在I类BRAF突变中占6.4%,在II/III类BRAF突变中占24.4%。
- 大多数患者接受化疗;11例接受靶向治疗,缓解率72.7%;14例接受PD-1/PD-L1免疫治疗,缓解率28.6%。
- BRAF突变型NSCLC总生存劣于BRAF野生型(HR 1.38,p=0.048)。
- BRAF靶向药物的中位治疗失败时间短于其他致癌驱动基因的获批靶向治疗(HR 1.97,p=0.05)。
临床怎么用
- 晚期NSCLC患者应进行BRAF突变检测及功能分类亚型分析。
- BRAF突变型NSCLC可考虑免疫检查点抑制剂治疗,因其对此类治疗敏感性较高。
- BRAF靶向治疗在中位治疗失败时间上劣于其他驱动基因的获批靶向治疗,需权衡治疗选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: BRAF mutations have been subtyped in three functional classes with different oncogenic modes of action. The clinical impact of BRAF mutational subtypes in non-small-cell lung cancer (NSCLC) remains to be defined. So far, ambiguous results were reported from analyses of heterogeneous patient cohorts. METHODS: We studied patients with metastatic or recurrent NSCLC who were sequentially enrolled in precision oncology programs at two large German lung cancer centres from 2009 to 2019. The study period allowed evaluating the specific impact of BRAF V600E-targeting. RESULTS: In a cohort of 72 patients, BRAF mutation subtyping revealed p.V600E mutations in 31 cases (43%), whereas 41 cases (57%) harboured 18 different BRAF mutational subtypes of functional classes II/III. Functionally relevant comutations were observed in 6.4% of class I, and 24.4% of class II/III BRAF mutations. Most patients were treated with chemotherapy. Targeted therapy was administered in 11 patients with a response rate of 72.7%. PD-1/PD-L1-immunotherapy was given in 14 patients with a response rate of 28.6%. Overall survival of patients with BRAF-mutated NSCLC was inferior (HR 1.38, p = 0.048) as compared to patients with BRAF wild-type cancers. Median time-to-treatment-failure with BRAF-targeting agents was shorter as compared to approved targeted therapy of other oncogenic drivers (HR 1.97, p = 0.05). Survival outcomes were not impacted by BRAF mutation subtype functional class. CONCLUSIONS: Patients with BRAF-mutated NSCLC have an inferior prognosis, which is not determined by BRAF mutation functional class. In contrast to NSCLC with other tractable driver mutations, BRAF-mutated NSCLC exhibit high susceptibility to immune checkpoint inhibitors.
引用
- Wiesweg M, Preuß C, Roeper J, et al. BRAF mutations and BRAF mutation functional class have no negative impact on the clinical outcome of advanced NSCLC and associate with susceptibility to immunotherapy. Eur J Cancer. 2021. PMID: 33872981. doi:10.1016/j.ejca.2021.02.036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。